Cyclosporine A inhibits in vitro replication of betaretrovirus associated with primary biliary cirrhosis

Liver International

Volumn 30, Issue 6, 2010, Pages 871-877

  Montano Loza, Aldo J ^a   Wasilenko, Shawn ^a   Bintner, Jasper ^a   Mason, Andrew L ^a  

^a UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

Author keywords

Betaretrovirus; Cyclosporine A; Liver transplantation; Primary biliary cirrhosis; Recurrent disease; Tacrolimus

Indexed keywords

ASPARTIC PROTEINASE; CYCLOPHILIN; CYCLOSPORIN A; CYCLOSPORIN A [4 N METHYLISOLEUCINE]; LAMIVUDINE; LOPINAVIR; TACROLIMUS; TENOFOVIR; VIRUS RNA; (MELLE-4)CYCLOSPORIN; ANTIVIRUS AGENT; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; PYRIMIDINONE DERIVATIVE; RNA DIRECTED DNA POLYMERASE;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; IN VITRO SELECTION; MOUSE; NONHUMAN; PRIMARY BILIARY CIRRHOSIS; RETROVIRUS INFECTION; RNA SYNTHESIS; VIRUS INHIBITION; VIRUS LOAD; VIRUS REPLICATION; ANIMAL; BIOSYNTHESIS; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECTS; GENETICS; GROWTH, DEVELOPMENT AND AGING; HUMAN; LIVER CIRRHOSIS, BILIARY; LIVER TRANSPLANTATION; METABOLISM; MOUSE MAMMARY TUMOR ONCOVIRUS; RECURRENT DISEASE; TUMOR CELL LINE; VIROLOGY;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE, TUMOR; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER CIRRHOSIS, BILIARY; LIVER TRANSPLANTATION; LOPINAVIR; MAMMARY TUMOR VIRUS, MOUSE; MICE; PYRIMIDINONES; RECURRENCE; RNA, VIRAL; RNA-DIRECTED DNA POLYMERASE; TACROLIMUS; VIRAL LOAD; VIRUS REPLICATION;

EID: 77954374041     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2010.02257.x     Document Type: Article

References (34)

1. Neuberger J. Recurrent primary biliary cirrhosis. Liver Transpl 2003, 9:539-46.
2. Charatcharoenwitthaya P, Pimentel S, Talwalkar JA. Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation. Liver Transpl 2007, 13:1236-45.
3. Guy JE, Qian P, Lowell JA, Peters MG. Recurrent primary biliary cirrhosis: peritransplant factors and ursodeoxycholic acid treatment post-liver transplant. Liver Transpl 2005, 11:1252-7.
4. Jacob DA, Neumann UP, Bahra M. Long-term follow-up after recurrence of primary biliary cirrhosis after liver transplantation in 100 patients. Clin Transpl 2006, 20:211-20.
5. Levitsky J, Hart J, Cohen SM, Te HS. The effect of immunosuppressive regimens on the recurrence of primary biliary cirrhosis after liver transplantation. Liver Transpl 2003, 9:733-6.
6. Neuberger J, Gunson B, Hubscher S, Nightingale P. Immunosuppression affects the rate of recurrent primary biliary cirrhosis after liver transplantation. Liver Transpl 2004, 10:488-91.
7. Sanchez EQ, Levy MF, Goldstein RM. The changing clinical presentation of recurrent primary biliary cirrhosis after liver transplantation. Transplantation 2003, 76:1583-8.
8. Montano-Loza AJ, Wasilenko S, Bintner J, Mason AL. Cyclosporine a protects against primary biliary cirrhosis recurrence after liver transplantation. Am J Transplant 2010, 10:852-8.
9. McAlister VC, Haddad E, Renouf E. Cyclosporin versus tacrolimus as primary immunosuppressant after liver transplantation: a meta-analysis. Am J Transplant 2006, 6:1578-85.
10. Wasilenko S, Mason AL. New insights from recurrent primary biliary cirrhosis in liver transplantation: the paradox of BEComing a fibroblast? Hepatology 2007, 45:837-40.
11. Hirschfield GM, Liu X, Xu C. Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants. N Engl J Med 2009, 360:2544-55.
12. Gershwin ME, Mackay IR. The causes of primary biliary cirrhosis: convenient and inconvenient truths. Hepatology 2008, 47:737-45.
13. Mason A, Xu L, Shen Z. Patients with primary biliary cirrhosis make anti-viral and anti-mitochondrial antibodies to mouse mammary tumor virus. Gastroenterology 2004, 127:1863-4.
14. Wasilenko ST, Mason GE, Mason AL. Primary biliary cirrhosis, bacteria and molecular mimicry: what's the molecule and where's the mimic? Liver Int 2009, 29:779-82.
15. Xu L, Shen Z, Guo L. Does a betaretrovirus infection trigger primary biliary cirrhosis? Proc Natl Acad Sci USA 2003, 100:8454-9.
16. Van de Water J, Gerson LB, Ferrell LD. Immunohistochemical evidence of disease recurrence after liver transplantation for primary biliary cirrhosis. Hepatology 1996, 24:1079-84.
17. Firpi RJ, Zhu H, Morelli G. Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation. Liver Transpl 2006, 12:51-5.
18. Nakagawa M, Sakamoto N, Enomoto N. Specific inhibition of hepatitis C virus replication by cyclosporin A. Biochem Biophys Res Commun 2004, 313:42-7.
19. Watashi K, Ishii N, Hijikata M. Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase. Mol Cell 2005, 19:111-22.
20. Franke EK, Yuan HE, Luban J. Specific incorporation of cyclophilin A into HIV-1 virions. Nature 1994, 372:359-62.
21. Franke EK, Luban J. Inhibition of HIV-1 replication by cyclosporine A or related compounds correlates with the ability to disrupt the Gag-cyclophilin A interaction. Virology 1996, 222:279-82.
22. Saini M, Potash MJ. Novel activities of cyclophilin A and cyclosporin A during HIV-1 infection of primary lymphocytes and macrophages. J Immunol 2006, 177:443-9.
23. Xu L, Sakalian M, Shen Z. Cloning the human betaretrovirus proviral genome from patients with primary biliary cirrhosis. Hepatology 2004, 39:151-6.
24. Arya S. Changes in retrovirus expression in mouse mammary tumor cells in culture. Cancer Res 1981, 41:1579-84.
25. Ma S, Boerner JE, TiongYip C. NIM811, a cyclophilin inhibitor, exhibits potent in vitro activity against hepatitis C virus alone or in combination with alpha interferon. Antimicrob Agents Chemother 2006, 50:2976-82.
26. Rosso R, Di Biagio A, Dentone C. Lopinavir/ritonavir exposure in treatment-naive HIV-infected children following twice or once daily administration. J Antimicrob Chemother 2006, 57:1168-71.
27. McDermid J, Chen M, Li Y. Reverse transcriptase activity in patients with primary biliary cirrhosis and other autoimmune liver disorders. Aliment Pharmacol Ther 2007, 26:587-95.
28. Zou KH, Tuncali K, Silverman SG. Correlation and simple linear regression. Radiology 2003, 227:617-22.
29. De Muth JE. Overview of biostatistics used in clinical research. Am J Health Syst Pharm 2009, 66:70-81.
30. Indik S, Mojiri A, Wong I. Isolation of a human betaretrovirus resembling mouse mammary tumor virus (MMTV) from patients with primary biliary cirrhosis (abstract). Retrovirology 2009, 6((Suppl. 2)):P55.
31. Kaul A, Stauffer S, Berger C. Essential role of cyclophilin A for hepatitis C virus replication and virus production and possible link to polyprotein cleavage kinetics. PLoS Patho 2009, 5:e1000546.
32. Mathy JE, Ma S, Compton T, Lin K. Combinations of cyclophilin inhibitor NIM811 with hepatitis C Virus NS3-4A Protease or NS5B polymerase inhibitors enhance antiviral activity and suppress the emergence of resistance. Antimicrob Agents Chemother 2008, 52:3267-75.
33. Johal H, Scott GM, Jones R. Mouse mammary tumour virus-like virus (MMTV-LV) is present within the liver in a wide range of hepatic disorders and unrelated to nuclear p53 expression or hepatocarcinogenesis. J Hepatol 2009, 50:548-54.
34. Selmi C, Ross SR, Ansari AA. Lack of immunological or molecular evidence for a role of mouse mammary tumor retrovirus in primary biliary cirrhosis. Gastroenterology 2004, 127:493-501.